Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
Public ClinicalTrials.gov record NCT01030861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Study identification
- NCT ID
- NCT01030861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- Teplizumab Drug
- Placebo infusion Drug
Drug
Eligibility (public fields only)
- Age range
- 8 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Oct 31, 2018
- Completion
- May 31, 2019
- Last update posted
- Aug 4, 2020
2010 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California in San Francisco | San Francisco | California | 94143 | — |
| University of California-San Francisco | San Francisco | California | 94143 | — |
| Stanford University | Stanford | California | 94305 | — |
| Barbara Davis Center for Childhood Diabetes/ University of Colorado | Denver | Colorado | 80045 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06519 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami | Miami | Florida | 33136 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| The Children's Mercy Hospital | Kansas City | Missouri | 64108 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15201 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| University of Texas | Dallas | Texas | 75390-9072 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Benaroya Research Institute | Seattle | Washington | 982101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01030861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2020 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01030861 live on ClinicalTrials.gov.